De-Regil Luz Maria, Jefferds Maria Elena D, Peña-Rosas Juan Pablo
Global Technical Services, Nutrition International, 180 Elgin Street, Suite 1000, Ottawa, ON, Canada, K2P 2K3.
Cochrane Database Syst Rev. 2017 Nov 23;11(11):CD009666. doi: 10.1002/14651858.CD009666.pub2.
Approximately 600 million children of preschool and school age are anaemic worldwide. It is estimated that at least half of the cases are due to iron deficiency. Point-of-use fortification of foods with micronutrient powders (MNP) has been proposed as a feasible intervention to prevent and treat anaemia. It refers to the addition of iron alone or in combination with other vitamins and minerals in powder form, to energy-containing foods (excluding beverages) at home or in any other place where meals are to be consumed. MNPs can be added to foods either during or after cooking or immediately before consumption without the explicit purpose of improving the flavour or colour.
To assess the effects of point-of-use fortification of foods with iron-containing MNP alone, or in combination with other vitamins and minerals on nutrition, health and development among children at preschool (24 to 59 months) and school (five to 12 years) age, compared with no intervention, a placebo or iron-containing supplements.
In December 2016, we searched the following databases: CENTRAL, MEDLINE, Embase, BIOSIS, Science Citation Index, Social Science Citation Index, CINAHL, LILACS, IBECS, Popline and SciELO. We also searched two trials registers in April 2017, and contacted relevant organisations to identify ongoing and unpublished trials.
Randomised controlled trials (RCTs) and quasi-RCTs trials with either individual or cluster randomisation. Participants were children aged between 24 months and 12 years at the time of intervention. For trials with children outside this age range, we included studies where we were able to disaggregate the data for children aged 24 months to 12 years, or when more than half of the participants were within the requisite age range. We included trials with apparently healthy children; however, we included studies carried out in settings where anaemia and iron deficiency are prevalent, and thus participants may have had these conditions at baseline.
Two review authors independently assessed the eligibility of trials against the inclusion criteria, extracted data from included trials, assessed the risk of bias of the included trials and graded the quality of the evidence.
We included 13 studies involving 5810 participants from Latin America, Africa and Asia. We excluded 38 studies and identified six ongoing/unpublished trials. All trials compared the provision of MNP for point-of-use fortification with no intervention or placebo. No trials compared the effects of MNP versus iron-containing supplements (as drops, tablets or syrup).The sample sizes in the included trials ranged from 90 to 2193 participants. Six trials included participants younger than 59 months of age only, four included only children aged 60 months or older, and three trials included children both younger and older than 59 months of age.MNPs contained from two to 18 vitamins and minerals. The iron doses varied from 2.5 mg to 30 mg of elemental iron. Four trials reported giving 10 mg of elemental iron as sodium iron ethylenediaminetetraacetic acid (NaFeEDTA), chelated ferrous sulphate or microencapsulated ferrous fumarate. Three trials gave 12.5 mg of elemental iron as microencapsulated ferrous fumarate. Three trials gave 2.5 mg or 2.86 mg of elemental iron as NaFeEDTA. One trial gave 30 mg and one trial provided 14 mg of elemental iron as microencapsulated ferrous fumarate, while one trial gave 28 mg of iron as ferrous glycine phosphate.In comparison with receiving no intervention or a placebo, children receiving iron-containing MNP for point-of-use fortification of foods had lower risk of anaemia prevalence ratio (PR) 0.66, 95% confidence interval (CI) 0.49 to 0.88, 10 trials, 2448 children; moderate-quality evidence) and iron deficiency (PR 0.35, 95% CI 0.27 to 0.47, 5 trials, 1364 children; moderate-quality evidence) and had higher haemoglobin (mean difference (MD) 3.37 g/L, 95% CI 0.94 to 5.80, 11 trials, 2746 children; low-quality evidence).Only one trial with 115 children reported on all-cause mortality (zero cases; low-quality evidence). There was no effect on diarrhoea (risk ratio (RR) 0.97, 95% CI 0.53 to 1.78, 2 trials, 366 children; low-quality evidence).
AUTHORS' CONCLUSIONS: Point-of-use fortification of foods with MNPs containing iron reduces anaemia and iron deficiency in preschool- and school-age children. However, information on mortality, morbidity, developmental outcomes and adverse effects is still scarce.
全球约有6亿学龄前和学龄儿童贫血。据估计,至少一半的病例是由缺铁引起的。用微量营养素粉(MNP)在食用点强化食品已被提议作为预防和治疗贫血的一种可行干预措施。它是指将铁单独或以粉末形式与其他维生素和矿物质混合,在家中或任何其他用餐场所添加到含能量的食物(不包括饮料)中。MNP可以在烹饪期间或之后添加到食物中,也可以在食用前立即添加,且并非旨在改善风味或颜色。
评估单独使用含铁MNP或与其他维生素和矿物质联合在食用点强化食品对学龄前(24至59个月)和学龄(5至12岁)儿童的营养、健康和发育的影响,并与无干预、安慰剂或含铁补充剂进行比较。
2016年12月,我们检索了以下数据库:Cochrane系统评价数据库、医学期刊数据库、荷兰医学文摘数据库、生物学文摘数据库、科学引文索引、社会科学引文索引、护理学与健康领域数据库、拉丁美洲和加勒比卫生科学数据库、IBECS、人口在线数据库和科学电子图书馆在线数据库。我们还在2017年4月检索了两个试验注册库,并联系了相关组织以识别正在进行和未发表的试验。
随机对照试验(RCT)和采用个体或整群随机化的半随机对照试验。干预时参与者为24个月至12岁的儿童。对于年龄范围超出此范围的儿童的试验,我们纳入了能够将24个月至12岁儿童的数据分开的研究,或者当超过一半的参与者在规定年龄范围内时纳入这些研究。我们纳入了表面健康儿童的试验;然而,我们也纳入了在贫血和缺铁普遍存在的环境中开展的研究,因此参与者在基线时可能患有这些疾病。
两位综述作者独立根据纳入标准评估试验的合格性,从纳入试验中提取数据,评估纳入试验的偏倚风险并对证据质量进行分级。
我们纳入了13项研究,涉及来自拉丁美洲、非洲和亚洲的5810名参与者。我们排除了38项研究,并识别出6项正在进行/未发表的试验。所有试验均将提供用于食用点强化的MNP与无干预或安慰剂进行比较。没有试验比较MNP与含铁补充剂(滴剂、片剂或糖浆)的效果。纳入试验的样本量从90至2193名参与者不等。6项试验仅纳入了年龄小于59个月的参与者,4项试验仅纳入了60个月及以上的儿童,3项试验纳入了年龄小于59个月和大于59个月的儿童。MNP含有2至18种维生素和矿物质。铁剂量从2.5毫克至30毫克元素铁不等。4项试验报告给予10毫克元素铁,形式为乙二胺四乙酸铁钠(NaFeEDTA)、螯合硫酸亚铁或微囊化富马酸亚铁。3项试验给予12.5毫克元素铁,形式为微囊化富马酸亚铁。3项试验给予2.5毫克或2.86毫克元素铁,形式为NaFeEDTA。1项试验给予30毫克元素铁,1项试验给予14毫克元素铁,形式为微囊化富马酸亚铁,而1项试验给予28毫克甘氨酸亚铁形式的铁。与无干预或接受安慰剂相比,接受含铁MNP进行食用点强化食品的儿童贫血患病率比值(PR)较低(0.66,95%置信区间(CI)0.49至0.88,10项试验,2448名儿童;中等质量证据)和缺铁情况(PR 0.35,95% CI 0.27至0.47,5项试验,1364名儿童;中等质量证据),且血红蛋白水平较高(平均差(MD)3.37 g/L,95% CI 0.94至5.80,11项试验,2746名儿童;低质量证据)。仅有1项纳入115名儿童的试验报告了全因死亡率(零病例;低质量证据)。对腹泻无影响(风险比(RR)0.97,95% CI 0.53至1.78,2项试验,366名儿童;低质量证据)。
用含铁MNP在食用点强化食品可降低学龄前和学龄儿童的贫血和缺铁情况。然而,关于死亡率、发病率、发育结局和不良反应的信息仍然匮乏。